Federal Ministry of Health (Nigeria)

Rising Prevalence of Chronic Diseases Propels Demand for Smart Hospital Beds in US and Europe

Retrieved on: 
Wednesday, July 26, 2023
Posture, Prevalence, Diabetes, Nursing, German, Cancer, BMBF, Federal Ministry of Health (Nigeria), Hospital, Patient, Workload, Conditional sentence, Growth, Pressure, Robotics, Health, Education, Software, Research

The US and Europe smart hospital beds market are set to experience robust expansion, driven by several factors, including the growing geriatric population, advancements in healthcare infrastructures, and strategic growth initiatives by smart hospital bed providers.

Key Points: 
  • The US and Europe smart hospital beds market are set to experience robust expansion, driven by several factors, including the growing geriatric population, advancements in healthcare infrastructures, and strategic growth initiatives by smart hospital bed providers.
  • With the rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders, along with an increasing number of lifestyle-related health conditions, the demand for smart hospital beds has surged.
  • One of the most promising opportunities in the smart hospital beds market is the development of robotic hospital beds.
  • Government support for such projects will likely drive the growth of the smart hospital beds market in the coming years.

Fujifilm and Qure.ai Join Hands With IHVN to Accelerate TB Screening in Rural Nigerian Communities

Retrieved on: 
Friday, August 12, 2022
Technology, Health, Radiology, Artificial Intelligence, Philanthropy, Other Science, Research, Medical Devices, Software, Infectious Diseases, General Health, Foundation, Hardware, Science, Death, Federal Ministry of Science and Technology, Heart failure, Oyo, Pneumonia, CEO, X-ray, Algorithm, Diagnosis, Technology, AI, Institute of Human Virology Nigeria, Leprosy, Leadership, Triage, Research, Tuberculosis, Office of the National Coordinator for Health Information Technology, University of Maryland, Baltimore, Founder, Health, Contact tracing, United States Agency for International Development, Federal Ministry of Health (Nigeria), International development, Partnership, National Tuberculosis Institute, Infection, COPD, Electricity, WHO, Virology, USAID, HIV, Solution, Party, TB, Medical imaging, Medical device, Pharmaceutical industry, Fujifilm

The partnership has enabled USAID funded IHVN to deploy ultra-portable X-ray machines embedded with AI for active case finding in Nigerian rural communities.

Key Points: 
  • The partnership has enabled USAID funded IHVN to deploy ultra-portable X-ray machines embedded with AI for active case finding in Nigerian rural communities.
  • Through our efforts (rural dwellers in communities with difficult terrains have been reached with TB care).
  • Our partnership with Fujifilm and Qure.ai for AI enabled TB screening is our most recent initiatives towards community outreach.
  • Together IHVN, Fujifilm and Qure.ai aim to strengthen the systems and structures for tuberculosis detection, treatment, and notification in rural Nigeria.

LUCA Science and Kyowa Kirin Announce Joint Research Agreement on Mitochondrial Disease Treatment With Novel Mitochondria Modality

Retrieved on: 
Wednesday, May 18, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Disease, Organelle, Lists of diseases, LUCA, Multimedia, Nephrology, Patient, Science, Muscle, Mitochondrion, D, Ministry, Kyowa Hakko Kirin, Research, Federal Ministry of Health (Nigeria), Brain, Degenerative disease, Mitochondrial disease, Ministry of Health, Labour and Welfare, Central nervous system, Technology, Heart, Therapy, Tissue, Pharmaceutical industry, Fine chemical, Health

LUCA Science Inc. (LUCA Science, Tokyo, Japan) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, Tokyo, Japan, TSE:4151) are pleased to announce they have entered into a research collaboration agreement on the treatment of mitochondrial diseases using platform of an innovative mitochondrial modality.

Key Points: 
  • LUCA Science Inc. (LUCA Science, Tokyo, Japan) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, Tokyo, Japan, TSE:4151) are pleased to announce they have entered into a research collaboration agreement on the treatment of mitochondrial diseases using platform of an innovative mitochondrial modality.
  • View the full release here: https://www.businesswire.com/news/home/20220517005653/en/
    Through this research collaboration, Kyowa Kirin, a leading specialty pharmaceutical company with deep disease science research knowledge based on diverse experiences in biopharmaceutical drug discovery, will leverage LUCA Science's proprietary functional mitochondria therapy platform to develop an innovative treatment for mitochondrial diseases.
  • LUCA Science has a deep-rooted commitment to finding a cure for mitochondrial disease.
  • We are excited to collaborate with Kyowa Kirin to advance research in mitochondrial disease treatment with our novel modality to further demonstrate the potential of mitochondria as a biopharmaceutical agent.

Orbis International Celebrates 23 Years of Achievements in Trachoma Elimination in Ethiopia this World Neglected Tropical Diseases Day

Retrieved on: 
Thursday, January 27, 2022
People, COVID-19, Water, Severe cognitive impairment, Azithromycin, Neglected tropical diseases, Mass drug administration, WHO, Missionary, Federal Ministry of Health (Nigeria), MDA, Ophthalmology, SNNPR, Knowledge, Achievement, World NTD Day, Orbis International, Hospital, University, School, Government, Organization, Prevalence, Research, Scar, MD-10, Organic, NTD, Southern Nations, Nationalities, and Peoples' Region, Recurrence, Eye, Disease, Sustainable development, Pharmaceutical industry, Trachoma, Orbis, Health

NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Ahead of World Neglected Tropical Diseases (NTD) Day, leading eye care nonprofit Orbis proudly celebrates 23 years of working to eliminate the blindness-causing infection trachoma in Ethiopia.

Key Points: 
  • NEW YORK, Jan. 27, 2022 /PRNewswire/ -- Ahead of World Neglected Tropical Diseases (NTD) Day, leading eye care nonprofit Orbis proudly celebrates 23 years of working to eliminate the blindness-causing infection trachoma in Ethiopia.
  • Trachoma is highly contagious, but it is easily treatable with antibiotics if it is caught early.
  • Orbis ultimately administered more than 12.3 million doses of the antibiotic Azithromycin in these regions, where the burden of trachoma remains particularly high.
  • "This World NTD Day, Orbis is proud to join the WHO and more than 300 other organizations coming together to combat NTDs.

DGAP-News: XPhyto Therapeutics Corp.: XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH

Retrieved on: 
Monday, December 6, 2021
Research, ODF, Gesellschaft mit beschränkter Haftung, POC, Sale, Federal Ministry of Health (Nigeria), Degenerative disease, CE, Industry, Acquisition, Company, CAGR, Saliva, PCR, German, Mouth, Influenza, Contract, Stomatitis, COVID-19, CSE, Intellectual property, 3A, Marketing, Education, Infection, Peri-implantitis, GERMANY, Therapy, Cannabinoid, IP, Fine chemical, Pharmaceutical industry

"The strategic acquisition of 3a is a transformative step in XPhyto's commercial strategy," said Peter Damouni, XPhyto director.

Key Points: 
  • "The strategic acquisition of 3a is a transformative step in XPhyto's commercial strategy," said Peter Damouni, XPhyto director.
  • "The integration of a highly innovative European biosensor development company places XPhyto at the forefront of the rapid point-of-care test industry, an explosive and technology driven sector.
  • This transaction is the second acquisition since going public in August 2019.
  • XPhyto completed the takeover of Vektor Pharma TF GmbH in September 2019.

Biognosys Supports Cancer Scout, a Large-Scale Multi-Omics Research Project to Accelerate Personalized Cancer Medicine

Retrieved on: 
Tuesday, October 12, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, Neoplasm, BMBF, Doctor of Philosophy, Genomics, Drug discovery, Protein, Cancer, Precision medicine, Software, Federal Ministry of Health (Nigeria), EUR, Siemens Healthineers, University Medical Center, Pathology, German, Education, Teaching hospital, CEO, Solution, UMG, Artificial intelligence, Pharmaceutical industry, Medical imaging, Fine chemical, Biognosys, University Hospital Göttingen, Siemens Healthineers, BIOGNOSYS, UNIVERSITY HOSPITAL GöTTINGEN, SIEMENS HEALTHINEERS

Cancer Scout is a large-scale joint research project led by University Medical Center Gttingen and Siemens Healthineers.

Key Points: 
  • Cancer Scout is a large-scale joint research project led by University Medical Center Gttingen and Siemens Healthineers.
  • The project received funding of EUR 10 million by the German Federal Ministry of Education and Research (BMBF)1.
  • The objective of Cancer Scout is to provide a new Artificial Intelligence tool for precision medicine in the fight against cancer.
  • Identifying these molecular changes can support early and accurate cancer diagnosis and predict personalized therapies for a patients tumor.